The omega-3 index

Clinical utility for therapeutic intervention

William Harris

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Red blood cell levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are a reflection of tissue levels and are determined by a complex interplay of metabolism and nutrition. Low levels of EPA+DHA in erythrocytes are associated with increased risk for sudden cardiac death. If levels of EPA+DHA in erythrocytes are determined using a strictly defined and standardized method, then the clinical significance of differing levels (previously defined in major research studies using this methodology) may be understood and applied in patient care. The Omega-3 Index, which is the EPA+DHA content of erythrocytes expressed as a percent of total identified fatty acids, was originally suggested as a marker of increased risk for death from coronary heart disease, but it can also be viewed as an actual risk factor, playing a pathophysiologic role in the disease. Optimal levels appear to be 8% or greater. At this stage of its development, the Omega-3 Index appears to fulfill many of the requirements for both a risk marker and a risk factor. Using the Omega-3 Index in the design of clinical studies might allow for a more efficient use of research resources.

Original languageEnglish (US)
Pages (from-to)503-508
Number of pages6
JournalCurrent Cardiology Reports
Volume12
Issue number6
DOIs
StatePublished - Nov 2010
Externally publishedYes

Fingerprint

Eicosapentaenoic Acid
Docosahexaenoic Acids
Erythrocytes
Sudden Cardiac Death
Therapeutics
Research
Coronary Disease
Patient Care
Fatty Acids

Keywords

  • Docosahexaenoic acid (DHA)
  • Eicosapentaenoic acid (EPA)
  • Omega-3 Index

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The omega-3 index : Clinical utility for therapeutic intervention. / Harris, William.

In: Current Cardiology Reports, Vol. 12, No. 6, 11.2010, p. 503-508.

Research output: Contribution to journalArticle

Harris, William. / The omega-3 index : Clinical utility for therapeutic intervention. In: Current Cardiology Reports. 2010 ; Vol. 12, No. 6. pp. 503-508.
@article{42abc1d1439d409a99ec2dc04991a283,
title = "The omega-3 index: Clinical utility for therapeutic intervention",
abstract = "Red blood cell levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are a reflection of tissue levels and are determined by a complex interplay of metabolism and nutrition. Low levels of EPA+DHA in erythrocytes are associated with increased risk for sudden cardiac death. If levels of EPA+DHA in erythrocytes are determined using a strictly defined and standardized method, then the clinical significance of differing levels (previously defined in major research studies using this methodology) may be understood and applied in patient care. The Omega-3 Index, which is the EPA+DHA content of erythrocytes expressed as a percent of total identified fatty acids, was originally suggested as a marker of increased risk for death from coronary heart disease, but it can also be viewed as an actual risk factor, playing a pathophysiologic role in the disease. Optimal levels appear to be 8{\%} or greater. At this stage of its development, the Omega-3 Index appears to fulfill many of the requirements for both a risk marker and a risk factor. Using the Omega-3 Index in the design of clinical studies might allow for a more efficient use of research resources.",
keywords = "Docosahexaenoic acid (DHA), Eicosapentaenoic acid (EPA), Omega-3 Index",
author = "William Harris",
year = "2010",
month = "11",
doi = "10.1007/s11886-010-0141-6",
language = "English (US)",
volume = "12",
pages = "503--508",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "6",

}

TY - JOUR

T1 - The omega-3 index

T2 - Clinical utility for therapeutic intervention

AU - Harris, William

PY - 2010/11

Y1 - 2010/11

N2 - Red blood cell levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are a reflection of tissue levels and are determined by a complex interplay of metabolism and nutrition. Low levels of EPA+DHA in erythrocytes are associated with increased risk for sudden cardiac death. If levels of EPA+DHA in erythrocytes are determined using a strictly defined and standardized method, then the clinical significance of differing levels (previously defined in major research studies using this methodology) may be understood and applied in patient care. The Omega-3 Index, which is the EPA+DHA content of erythrocytes expressed as a percent of total identified fatty acids, was originally suggested as a marker of increased risk for death from coronary heart disease, but it can also be viewed as an actual risk factor, playing a pathophysiologic role in the disease. Optimal levels appear to be 8% or greater. At this stage of its development, the Omega-3 Index appears to fulfill many of the requirements for both a risk marker and a risk factor. Using the Omega-3 Index in the design of clinical studies might allow for a more efficient use of research resources.

AB - Red blood cell levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are a reflection of tissue levels and are determined by a complex interplay of metabolism and nutrition. Low levels of EPA+DHA in erythrocytes are associated with increased risk for sudden cardiac death. If levels of EPA+DHA in erythrocytes are determined using a strictly defined and standardized method, then the clinical significance of differing levels (previously defined in major research studies using this methodology) may be understood and applied in patient care. The Omega-3 Index, which is the EPA+DHA content of erythrocytes expressed as a percent of total identified fatty acids, was originally suggested as a marker of increased risk for death from coronary heart disease, but it can also be viewed as an actual risk factor, playing a pathophysiologic role in the disease. Optimal levels appear to be 8% or greater. At this stage of its development, the Omega-3 Index appears to fulfill many of the requirements for both a risk marker and a risk factor. Using the Omega-3 Index in the design of clinical studies might allow for a more efficient use of research resources.

KW - Docosahexaenoic acid (DHA)

KW - Eicosapentaenoic acid (EPA)

KW - Omega-3 Index

UR - http://www.scopus.com/inward/record.url?scp=77958502858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958502858&partnerID=8YFLogxK

U2 - 10.1007/s11886-010-0141-6

DO - 10.1007/s11886-010-0141-6

M3 - Article

VL - 12

SP - 503

EP - 508

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 6

ER -